Literature DB >> 3291595

Arrhythmias, catecholamines and electrolytes.

J G Cleland1, H J Dargie.   

Abstract

The prognosis in patients with heart failure secondary to left ventricular dysfunction is poor. Although survival can be related to the extent of cardiac functional impairment, many patients die suddenly rather than in refractory heart failure. Ambulatory electrocardiography has revealed a high prevalence of simple and complex ventricular arrhythmias in these patients, which was the most important predictor of subsequent mortality in our patients. Factors predisposing to arrhythmias are many, but increased catecholamines and electrolyte abnormalities are among the more obvious. In patients who have undergone treatment for congestive heart failure, serum and total body potassium are reduced, and this is closely and inversely related to the state of activation of the renin-angiotensin system. Renin and noradrenaline are also closely and directly correlated, while both are inversely related to the arterial pressure. Treatment with angiotensin-converting enzyme inhibitors tends to reverse these neuroendocrine and electrolyte abnormalities and reduces the frequency of ventricular arrhythmias. Whether this will have a favorable impact on mortality, and, in particular, on sudden death, remains to be seen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3291595     DOI: 10.1016/s0002-9149(88)80086-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Recent Advances in Pharmacological Management of Hypertension in Diabetic Patients with Nephropathy : Effects of Antihypertensive Drugs on Kidney Function and Insulin Sensitivity.

Authors:  Tsuneharu Baba; Takashi Ishizaki
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  Variations in potassium concentration modify the inhibitory effect of lorcainide on myocardial Na(+)-K(+)-ATPase activity.

Authors:  A A Almotrefi; N Dzimiri
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

4.  Are beta blockers still necessary for all survivors of acute myocardial infarction?

Authors:  Daisaku Nakatani; Yasuhiko Sakata
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

5.  Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure.

Authors:  Wei Jiang; Christopher O'Connor; Susan G Silva; Maragatha Kuchibhatla; Michael S Cuffe; Dwayne D Callwood; Bosh Zakhary; Elizabeth Henke; Rebekka M Arias; Ranga Krishnan
Journal:  Am Heart J       Date:  2008-07-07       Impact factor: 4.749

6.  Long-term impact of β-blocker in elderly patients without myocardial infarction after percutaneous coronary intervention.

Authors:  Tatsuya Fukase; Tomotaka Dohi; Takuma Koike; Hidetoshi Yasuda; Mitsuhiro Takeuchi; Norihito Takahashi; Yuichi Chikata; Hirohisa Endo; Shinichiro Doi; Hiroki Nishiyama; Iwao Okai; Hiroshi Iwata; Shinya Okazaki; Katsumi Miyauchi; Hiroyuki Daida; Tohru Minamino
Journal:  ESC Heart Fail       Date:  2021-11-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.